Shorter chemo shows promise for HIV patients with lymphoma
NCT ID NCT00006436
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study tested a shorter course of a chemotherapy combination called EPOCH-R in 68 people with HIV and a type of lymphoma. The goal was to see if reducing the amount of chemotherapy could still control the cancer while causing less damage to the immune system. Participants received treatment every 3 weeks for 3 to 6 cycles, and their response was monitored with scans and blood tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab)
- What this could lead to
- If successful, this approach could offer a shorter, less immune-damaging chemotherapy regimen for people with HIV and lymphoma, potentially reducing infections and future cancer risks.
- What could go wrong
- This is a small, completed phase 2 trial with no control group, so results are preliminary. The combination still carries significant toxicity risks, and long-term outcomes are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, AIDS-RELATED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to lock in remission for rare lymphoma
- New hope for HIV patients with aggressive lymphoma: early trial launches
- Scientists seek tissue samples to unlock HIV-Cancer mysteries
- Gene therapy takes on HIV and cancer in one shot
- New combo tackles rare, aggressive lymphoma
- New PET scan targets hidden cancers with precision